To integrate and deliver cutting edge technology solutions that strengthen the nation’s health and preparedness.
What Sets Us Apart
We have decades of experience integrating the best of breed technologies into reliable and sustainable solutions. We understand that technology not only needs to perform as specified, but must also be cost effective, reliable, sustainable, and meet the end-user's needs.
David Tilles, President and Founder of ASELL, has over 35 years of experience leading both small and large organizations in the development, integration, and sustainment of complex systems in industries ranging from industrial automation to biodefense. Prior to founding ASELL, Mr. Tilles spent over 30 years at Northrop Grumman, rising to the level of Vice President of CBRNE Defense Systems. In that role, he led an organization that grew to one of the largest CBRNE defense businesses in the industry, with a broad range of technologies and US Government customers. After retiring from Northrop Grumman and prior to founding ASELL, he spent several years as an independent consultant helping small businesses win and execute government programs. Mr. Tilles has a BES in Materials Science and an MS in Technical Management, both from the Johns Hopkins University, and has taken management courses at the University of Chicago and Harvard Business School.
Ken Damer is the Vice President of Engineering and Technology Development at ASELL. Mr. Damer has over 19 years of experience in various engineering and program management roles serving a broad range of customers. He has led the development of a variety of CBRNE technologies and platforms over his career, including radiological biodosimetry, biological threat agent detection/identification (PCR, immunoassay, UV-LIF, etc.), aerosol particle collection and concentration, and microfluidics. Mr. Damer was previously a Program and Engineering Manager at Northrop Grumman, where he managed complex technical efforts spanning the entire program lifecycle, from early concept development all the way through to post-production operations and maintenance. He holds degrees in engineering and technical management from Worcester Polytechnic Institute and Johns Hopkins University.
Matt Snyder, PMP, is Vice President of Operations at ASELL and has 18 years of experience in engineering and program management. Mr. Snyder was previously a Program Manager at Northrop Grumman where he led a variety of medical device and CBRNE defense programs that involved complex technology integration and required a deep understanding of customer needs and requirements. Mr. Snyder began his career in engineering and has worked in product development, large scale production, deployment, and sustainment programs. Most recently he has led program management activities in support of the CytoRADx™ Biodosimetry system development. Mr. Snyder graduated from the University of Rochester with a Bachelor’s degree in Biology and a Master’s in Mechanical Engineering, and has completed a certificate in Program Management from the University of California Irvine.
Richard Kowalski, Ph.D., Chief Scientist and Principal Investigator at ASELL, received his doctorate in Molecular Biology at Vanderbilt University. Dr. Kowalski has over 30 years of experience developing and supporting in vitro diagnostic devices including confirmatory assays for HIV, HTLV-I/II, and Lyme disease along with IDE experience using mesenchymal stem cells for bone repair, cancer treatment, and gene therapy and platelet-rich plasma support for wound care. Prior to joining ASELL, Dr. Kowalski led Medical and Clinical Affairs teams and early Product Development at Cylex Inc. As lead of Product Development at Cylex, Dr. Kowalski brought the Cylex Immune Cell Function Assay (ImmuKnow®) from bench to bedside by leading the clinical and analytical validation studies to support clearance of ImmuKnow for marketing in the US. Prior to joining ASELL, Dr. Kowalski was the Principal Investigator at Northrop Grumman where he led assay development, clinical and non-clinical studies of the CytoRADx System. Dr. Kowalski provides ASELL the experience required to validate the safety and efficacy of high-complexity assays and detection systems.
Joshua D. Levin, Ph.D., RAC(US), Director of Quality Assurance and Regulatory Affairs at ASELL, received his B.A. from Brandeis University and his Ph.D. from Harvard University in Biochemistry and Molecular Biology. Prior to joining ASELL, Dr. Levin was responsible for overseeing quality assurance aspects of the design control and risk management processes at Personal Genome Diagnostics (PGDx), and for achieving ISO 13485:2016 certification for the company’s quality management system. Dr. Levin was previously a reviewer and postmarket team lead in the Office of In Vitro Diagnostics and Radiological Health (OIR), CDRH, FDA where he was responsible for quality system reviews and compliance activities for IVD products, with a focus on immunology, hematology, and molecular diagnostic devices. Prior to his 8 years at FDA, Dr. Levin worked for 15 years in R&D and process development in various IVD and research products firms.
Tom Hynes, Director of Business Management at ASELL, has over 33 years of experience in Finance, Contracts, Subcontracts, Business Strategy and Program Management at Grumman Aerospace, Norden Systems and Northrop Grumman Corporations. Prior to supporting ASELL, Mr. Hynes was the Contracts and Subcontracts manager during the establishment of CBRNE Defense Systems at Northrop Grumman and later became the Business Director (finance, contracts & subcontracts) for the division. Mr. Hynes has managed a multitude of large and small business areas, as well as several joint ventures. He also was Business Director for Northrop Grumman Electronic Systems Sector’s annual internal research & development funds and International Strategy. He holds degrees in Business Administration, Economics and an MBA in Finance.
ASELL is committed to enhancing the nation’s resilience to 21st Century health and security challenges. We achieve and maintain quality through continuous improvement of our processes, the suitability and effectiveness of our Quality Management System, and through our commitment to deliver quality products and services that fulfill customer and regulatory requirements.